FDA Approves Safinamide (Xadago®) as an Add-on Treatment for Parkinson’s
March 22, 2017

The Parkinson’s Foundation alerts the community that the US Food and Drug Administration (FDA) has approved safinamide tablets (Xadago®) as an add-on treatment for people with Parkinson’s who are currently taking carbidopa/levodopa and experiencing “off” episodes. The FDA announced the approval on March 21.

Carbidopa/levodopa is the gold-standard therapy for Parkinson’s movement symptoms. As Parkinson’s progresses, many people experience “off” periods in which the drug wears off and movement symptoms return before the next dose. "Off" periods can be very disabling.

April 28, 2017

Join PDF and event Co-Chairs Rehana Ashraf, Kate Evans and Anne Greene for Celebrate Spring Boston. Enjoy a night of cocktails, hors d’oeuvres, dancing and a silent auction.